TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05448651
Drug: UPB-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT05448651
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT05149807
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Tegafur Gimeracil Oteracil Potassium Oxaliplatin
Study: NCT04626141
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be dispensed as a 30-day supply of disposable pen injections.
Study: NCT06049797
Drug: Desvenlafaxine
Normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT06298344
Drug: Thiamine
Normalized name: Thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily Thiamine 100 mg in 28 days
Study: NCT06049797
Drug: Any other SSRI/SNRI not already specified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT06312761
Drug: Testosterone Undecanoate 237 MG Oral Capsule
Normalized name: testosterone undecanoate 237 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone Undecanoate 237 MG Oral Capsule
Study: NCT06181045
Drug: LY3410738
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT06181045
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT06516445
Drug: CAPEOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine: 1000 mg/m2, BID, PO，D1-14, Q3W, C1-C4； Oxaliplatin: 130mg/m2, D1, ivgtt, 0-2h，Q3W，C1-4
Study: NCT05073094
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equivalent volume of placebo (saline) as a bolus before aortic cross-clamping and in the cardioplegic solution
Study: NCT05920707
Drug: Intranasal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer placebo intranasally, 6 individual 0.1 ml puffs, three puffs per nostril one every 30 seconds.
Study: NCT05037409
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT05036473
Drug: WD-1603 Carbidopa-Levodopa Extended-Release Tablets
Normalized name: carbidopa / levodopa Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taking WD-1603 tablets or placebo orally three times a day, in the morning before meals, and the second and third medications will be taken after meals, once every 5 hours (±30 minutes).
Study: NCT05036473
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets-matching the active groups.
Study: NCT05123040
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 1 (starting dose) = 1 mg/kg~* Dose level 2 = 0.5 mg/kg~* Dose level 3 = 0.25 mg/kg~* Dose level 4 = 0.1 mg/kg~* Dose level 5 = 0 mg/kg~  • If dose level 1 is determined to be below the Recommended Phase 2 Dose (RP2D), the dose will be escalated:~* Dose level -1 = 1.5 mg/kg~* Dose level -2 = 2 mg/kg
Study: NCT06528691
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intravenous (IV)
Study: NCT04980391
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of placebo, administered intramuscularly in the non-dominant arm, at Day 1.
Study: NCT06373978
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50mg every 8hours as needed for pain
Study: NCT06702098
Drug: iNK cells
Normalized name: cuttle fish ink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induced pluripotent stem cells derived NK cells.
Study: NCT04828083
Drug: Saline IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline of 1.5 mg/kg bolus followed by a 1.5 mg/kg/h infusion continuing to the end of phase 1 of post anesthesia care unit
Study: NCT05750797
Drug: Oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: The prescription of OCS will be analyzed. OCS included betamethasone, deflazacort, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, and triamcinolone.
Study: NCT06072560
Drug: Adezunap (AP707)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
Study: NCT06072560
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
Study: NCT06703788
Drug: A fiixed combination of Chinese herbal medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: a fixed combination of Chinese herbal medicine with Ma-Xing-Gang-Shi-Tang (initiate at 2 grams, with increments of 0.5 grams every 2-4 weeks, up to a maximum dose of 4 grams once daily) and Coptis chinensis (initiate at 0.5 grams, with increments of 0.5 grams every 2-4 weeks, up to a maximum dose of 1 gram once daily), twice a day
Study: NCT04665843
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
Study: NCT06499285
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered subcutaneously every 4 weeks
Study: NCT04762901
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV
Study: NCT04762901
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV
Study: NCT05761756
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of caffeine
Study: NCT06650007
Drug: HRS9531 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS9531 Injection
Study: NCT06650007
Drug: HRS9531 Placebo Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS9531 Placebo Injection
Study: NCT05110144
Drug: Placebo 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mg tablet with no active study ingredient for 4 weeks
Study: NCT05110144
Drug: Placebo 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60mg tablet with no active study ingredient for 4 weeks
Study: NCT06290063
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo arm; capsules produced by Ecofibre/Ananda Hemp will be used
Study: NCT05234619
Drug: Group one ( lidocaine or control LE ) Early deflation
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: This will be conducted on 20 trauma patients group one who will be present for both elective and emergency Hand and Forearm surgery After establishing noninvasive arterial blood pressure, ECG, peripheral oxygen saturation monitoring, two venous cannulae will be inserted: one in a vein in the dorsum of operative hand and the other in the opposite hand for crystalloid infusion.~The opposite arm will be elevated for 2 minutes, and using an Esmarch bandage, the venous capacitance of the arm will be emptied. Then, a double-pneumatic tourniquet will be applied. The proximal tourniquet will be inflated to a pressure of 250 mmHg and circulatory isolation of the arm will be confirmed by inspection, lack of radial pulse and failure of pulse oximetry tracing of ipsilateral index finger then Esmarch bandage will be released then induction of lidocaine for intravenous regional anesthesia ( Bier block ) and Early deflation of distal tourniquet occurs after 20 minutes of IVRA induction
Study: NCT05234619
Drug: Group two ( lidocaine , ketorolac LKE ) Early deflation
Approvals — FDA: no, EMA: no, PMDA: no
Description: As the first intervention this will be conducted on group two but ketorolac will be combined with lidocaine in intravenous regional anesthesia
Study: NCT05234619
Drug: Group four ( lidocaine , ketorolac LKL ) Late deflation
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: As the first intervention this will be conducted on group four but late deflation of distal tourniquet in intravenous regional anesthesia after 40 minutes of induction of lidocaine and ketorolac for IVRA .
Study: NCT06799000
Drug: Placebo 1
Normalized name: placebo 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to remibrutinib Dose A (oral)
Study: NCT06799000
Drug: Placebo 2
Normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to remibrutinib Dose B (oral)
Study: NCT06099184
Drug: EYP-1901
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal Injection
Study: NCT05154370
Drug: Intravenous steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study does not limit treatment methods. Patients commonly use high-dose intravenous steroid therapy (HD-S) during acute stage. Immunomodulatory therapies are necessary for the remission stage. All drugs are used in accordance with relevant guidelines.
Study: NCT04932187
Drug: Capecitabine, Camrelizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a single-arm study with all patients receiving these two drugs.
Study: NCT04705844
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (4 SC injections of equal volume administered at separate sites on the thigh or abdomen)
Study: NCT05001763
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose, 2mg, tablet.
Study: NCT06703463
Drug: MK-1167
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via oral capsule per dosing regimen.
Study: NCT06320080
Drug: TQB2223 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2223 is an anti- lymphocyte activation gene-3 (LAG-3) antibody.
Study: NCT05667415
Drug: disulfiram and cisplatin
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: on the first day of treatment, patients were given intravenous drip of 80mg/m2 cisplatin, and 21 days was a course of treatment, lasting for 6 courses. Take 400mg disulfiram orally every day, and continue to use it until the end of chemotherapy. According to the patient's tolerance to disulfiram, the dose of disulfiram can be re-evaluated during the treatment, and the lowest dose is 125mg per day. The clinical symptoms, signs and adverse reactions of patients were observed, and the treatment effect of patients was evaluated after two consecutive cycles with 3 weeks as a cycle.
Study: NCT05672394
Drug: lidocaine with epinephrine
Normalized name: epinephrine / lidocaine Cartridge [Xylocaine with Epinephrine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ccs of 1.5% lidocaine with 1:200,000 epinephrine
Study: NCT05154968
Drug: Citrate buffer
Normalized name: Citrate Buffer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC infusion.
Study: NCT05876832
Drug: XY0206
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form:Tablet;Multiple dose phase:Take the medicine once a day,37.5mg at a time.4 weeks of continuous medication is one course of treatment. After the first course of treatment, the subjects can continue to receive the experimental drug treatment until the subjects meet the withdrawal criteria.
Study: NCT05350371
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo tablets will be an exact replica of the pirfenidone tablet.
Study: NCT05984784
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Placebo Intravenous Infusion
Study: NCT05053139
Drug: NNC0365-3769 (Mim8)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mim8 will be injected into a skinfold on the stomach with a thin needle either once a week or once a month.
Study: NCT05206877
Drug: Insulin, 4 units
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical insulin 100 U/ml, 1 drop per day
Study: NCT05206877
Drug: Insulin, 20 units
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical insulin 500 U/ml, 1 drop per day
Study: NCT05206877
Drug: insulin, 4 units twice daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop of low dose insulin twice daily.
Study: NCT05206877
Drug: insulin, 20 units twice daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop of high dose insulin twice daily
Study: NCT05206877
Drug: insulin, 4 units three times daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop of low dose insulin three times daily.
Study: NCT05206877
Drug: insulin, 20 units three times daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop of high dose insulin three times daily.
Study: NCT05593549
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcrystalline cellulose will be given at a dose of 10g mixed in 500 mL of water to be consumed 1 time per day for 14 days
Study: NCT06406153
Drug: Antipyretic
Normalized name: ANTIPYRETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: An antipyretic is administered one hour before the infusion.
Study: NCT05707741
Drug: dexmetomedine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ml mixture of saline 49 ml and dexmedetomidine 100 μg,
Study: NCT05707741
Drug: Dexmetomedine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ml mixture of saline 48 ml and dexmedetomidine 200 μg
Study: NCT06563895
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-active control administered orally twice daily (BID)
Study: NCT02043821
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 14days
Study: NCT05134727
Drug: AZD5055
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy participants will receive AZD5055
Study: NCT05134727
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy participants will receive placebo
Study: NCT05634447
Drug: Drug: CKD-391, QD, PO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: CKD-331, D337 QD, PO
Study: NCT06638671
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will consume metformin or placebo in a randomized order. Participants will complete exercise visits during each treatment phase.
Study: NCT05606913
Drug: IBI362
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI362 administered subcutaneously (SC) once a week.
Study: NCT05896254
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT05310253
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pill
Study: NCT06153251
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT06523465
Drug: Simvastatin combined with Amlodipine besylate
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-month treatment of Simvastatin combined with Amlodipine besylate
Study: NCT06523465
Drug: Simvastatin combined with Spironolactone and Amlodipine besylate.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month treatment of Simvastatin combined with Spironolactone and Amlodipine besylate.
Study: NCT06523465
Drug: Amlodipine besylate combined Spironolactone
Normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-month treatment of Amlodipine besylate combined with Spironolactone
Study: NCT05329766
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered as specified in the treatment arm
Study: NCT05329766
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered as specified in the treatment arm
Study: NCT05514496
Drug: NX-019
Normalized name: Replesta NX
Approvals — FDA: no, EMA: no, PMDA: no
Description: NX-019 will be administered orally.
Study: NCT04918758
Drug: Standard Care Arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate enemas 2g twice daily for 8 weeks, this is standard care in patients with haemorrhagic radiation proctopathy in the short term
Study: NCT05548543
Drug: HCP2202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once per period.
Study: NCT05548543
Drug: RLD2202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once per period.
Study: NCT05548543
Drug: RLD2203
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once per period.
Study: NCT05675072
Drug: FB2001
Approvals — FDA: no, EMA: no, PMDA: no
Description: FB2001 for Inhalation will be reconstituted with normal saline prior to nebulized inhalation. FB2001 will be administered by nebulized inhalation.
Study: NCT05675072
Drug: FB2001 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: FB2001 placebo will be reconstituted with normal saline prior to nebulized inhalation. FB2001 placebo will be administered by nebulized inhalation.
Study: NCT06233058
Drug: Drospirenone+ Ethinyl Estradiol Tablets-Test product
Normalized name: drospirenone / ethinyl estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drospirenone (3 mg) + Ethinyl Estradiol (0.03 mg) Tablets Manufactured by: Umeda Company Limited, Thailand
Study: NCT06233058
Drug: Drospirenone+ Ethinyl Estradiol Tablets-Reference product
Normalized name: drospirenone / ethinyl estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drospirenone (3 mg) + Ethinyl Estradiol (0.03 mg) Tablets Manufactured by: Bayer AG, Berlin, Germany
Study: NCT05257083
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered intravenously.
Study: NCT05130671
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care treatment as per the hospital guidelines
Study: NCT05870579
Drug: [68Ga]Ga-NeoB
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[68Ga\]Ga-NeoB serves as a radioactive imaging compound to be used for PET imaging for localization of GRPR positive lesions, at screening, potentially at Cycle 2 Day 15 visit, and between 4 and 8 weeks after the last administered dose of \[177Lu\]Lu-NeoB.~\[68Ga\]Ga-NeoB will be administered as a single intravenous (i.v.) dose.
Study: NCT05870579
Drug: [177Lu]Lu-NeoB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants will receive \[177Lu\]Lu-NeoB once every cycle
Study: NCT05369390
Drug: NNC0487-0111 A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive NNC0487-0111 A tablet once daily.
Study: NCT05369390
Drug: NNC0487-0111 B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive NNC0487-0111 B tablet once daily.
Study: NCT06554873
Drug: Nicorette 4Mg Chewing Gum
Normalized name: Nicorette 4mg Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4mg Nicorette gum (flavors - cinnamon surge, fruit chill, and mint); as needed maximum usage 24 weeks.
Study: NCT06554873
Drug: Nicorette Lozenge Product
Normalized name: Nicorette Lozenge Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4mg Nicorette mint lozenge; as needed maximum usage 24 weeks.
Study: NCT06355349
Drug: Reference Drug or Test Drug
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, Oral, QD for 1 Day, Washout period is more than 21 days after administration
Study: NCT04323475
Drug: Xeroform
Normalized name: DRESSING,XEROFORM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care will consist of Xeroform primary dressing and Kenacomb topical antibiotic cream (for wounds with signs of localized infection)
Study: NCT05145660
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent cisplatin (100 mg/m², d1-3, Q3w, maximum to three cycles); The application of induction chemotherapy and consolidation chemotherapy is dependent on the physician's discretion.
Study: NCT05850494
Drug: HFA MDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Dose formulation: MDI~* Unit dose strength(s): Reference (propellant only)~* Dosage Level: 4 inhalations, single dose~* Route of administration: Oral inhalation~* Participants will receive treatment A in 1 or 2 possible sequences AB or BA
Study: NCT04739371
Drug: Insulin, Regular, Human
Normalized name: insulin, regular, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: The spray will last a few seconds and then the participant will be asked to sniff to aid the drug into the nose. The device (i.e. ViaNase) is an atomizer that uses its patented technology that turns the liquid into a fine mist of droplets to facilitate the drug along the nose to brain pathway. Each nostril will receive this administration 2 times for a total of 40 IUs or 0.4 mL of liquid.
Study: NCT04739371
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The spray will last a few seconds and then the participant will be asked to sniff to aid the saline into the nose. The device (i.e. ViaNase) is an atomizer that uses its patented technology that turns the liquid into a fine mist of droplets to facilitate the drug along the nose to brain pathway. Each nostril will receive this administration 2 times for a total of 40 IUs or 0.4 mL of liquid.
Study: NCT06239623
Drug: JSI-1187
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use ERK inhibitor JSI-1187 to treat solid tumor
Study: NCT05201794
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for each dose level as tablet will be administered orally.
Study: NCT05945147
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: An escalating dose of normal saline (0.15 to 0.4 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days
Study: NCT06564467
Drug: JMT202
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection
Study: NCT06564467
Drug: Placrbo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection
Study: NCT05669924
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for methylphenidate
Study: NCT04944862
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered intravenously
Study: NCT06119958
Drug: DWC202313
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental Drug 1
Study: NCT06119958
Drug: DWC202314
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental Drug 2
Study: NCT06567522
Drug: Lumbar Erector Spinae Plane Block. L bupivacaína 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided ESP-L shall be carried out at the L3-14 level with 30 mL of levobupivacaine 0.25%
Study: NCT05245448
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05703672
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One pill (white) once daily for days 1-3, one pill (white) twice daily for days 4-7 and one pill (blue) twice daily from day 8 through week 12.